Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 477

1.

Mechanisms Underlying the Antidepressant Response of Acupuncture via PKA/CREB Signaling Pathway.

Jiang H, Zhang X, Wang Y, Zhang H, Li J, Yang X, Zhao B, Zhang C, Yu M, Xu M, Yu Q, Liang X, Li X, Shi P, Bao T.

Neural Plast. 2017;2017:4135164. doi: 10.1155/2017/4135164. Epub 2017 Apr 16.

2.

New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.

Huang YJ, Lane HY, Lin CH.

Neural Plast. 2017;2017:4605971. doi: 10.1155/2017/4605971. Epub 2017 Apr 11. Review.

3.

Deep brain stimulation in the bed nucleus of the stria terminalis and medial forebrain bundle in a patient with major depressive disorder and anorexia nervosa.

Blomstedt P, Naesström M, Bodlund O.

Clin Case Rep. 2017 Mar 31;5(5):679-684. doi: 10.1002/ccr3.856. eCollection 2017 May.

4.

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications.

Cohen IV, Makunts T, Atayee R, Abagyan R.

Sci Rep. 2017 May 3;7(1):1450. doi: 10.1038/s41598-017-01590-x.

5.

Talking sensibly about depression.

Patel V.

PLoS Med. 2017 Apr 4;14(4):e1002257. doi: 10.1371/journal.pmed.1002257. eCollection 2017 Apr.

6.

Is the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?

Çiftçi A, Ulaş H, Topuzoğlu A, Tunca Z.

Noro Psikiyatr Ars. 2016 Sep;53(3):245-252. doi: 10.5152/npa.2015.10141. Epub 2016 Sep 1.

7.

Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial.

Anderson IM, Blamire A, Branton T, Clark R, Downey D, Dunn G, Easton A, Elliott R, Elwell C, Hayden K, Holland F, Karim S, Loo C, Lowe J, Nair R, Oakley T, Prakash A, Sharma PK, Williams SR, McAllister-Williams RH; Ketamine-ECT Study team..

Lancet Psychiatry. 2017 May;4(5):365-377. doi: 10.1016/S2215-0366(17)30077-9. Epub 2017 Mar 27.

8.

Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Pirazzini M, Rossetto O, Eleopra R, Montecucco C.

Pharmacol Rev. 2017 Apr;69(2):200-235. doi: 10.1124/pr.116.012658. Review.

9.

Childhood neglect predicts the course of major depression in a tertiary care sample: a follow-up study.

Paterniti S, Sterner I, Caldwell C, Bisserbe JC.

BMC Psychiatry. 2017 Mar 28;17(1):113. doi: 10.1186/s12888-017-1270-x.

10.

Effects of hyperthermic baths on depression, sleep and heart rate variability in patients with depressive disorder: a randomized clinical pilot trial.

Naumann J, Grebe J, Kaifel S, Weinert T, Sadaghiani C, Huber R.

BMC Complement Altern Med. 2017 Mar 28;17(1):172. doi: 10.1186/s12906-017-1676-5.

11.

Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.

Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV, Charney DS, Murrough JW.

Transl Psychiatry. 2017 Mar 21;7(3):e1065. doi: 10.1038/tp.2017.31.

12.

Early Symptom Trajectories as Predictors of Treatment Outcome for Citalopram Versus Placebo.

Zilcha-Mano S, Roose SP, Brown PJ, Rutherford BR.

Am J Geriatr Psychiatry. 2017 Jun;25(6):654-661. doi: 10.1016/j.jagp.2017.02.001. Epub 2017 Feb 3.

PMID:
28318797
13.

A Preliminary Study of Genetic Variation in the Dopaminergic and Serotonergic Systems and Genome-wide Additive Genetic Effects on Depression Severity and Treatment Response.

Palmer RH, Beevers CG, McGeary JE, Brick LA, Knopik VS.

Clin Psychol Sci. 2017 Jan;5(1):158-165. doi: 10.1177/2167702616651075. Epub 2016 Oct 19. No abstract available.

PMID:
28316879
14.

Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.

Katz DA, Locke C, Greco N, Liu W, Tracy KA.

Brain Behav. 2017 Feb 9;7(3):e00628. doi: 10.1002/brb3.628. eCollection 2017 Mar.

15.

Gene expression and proliferation biomarkers for antidepressant treatment resistance.

Breitfeld J, Scholl C, Steffens M, Laje G, Stingl JC.

Transl Psychiatry. 2017 Mar 14;7(3):e1061. doi: 10.1038/tp.2017.16.

16.

Neurocognitive Predictors of Response in Treatment Resistant Depression to Subcallosal Cingulate Gyrus Deep Brain Stimulation.

McInerney SJ, McNeely HE, Geraci J, Giacobbe P, Rizvi SJ, Ceniti AK, Cyriac A, Mayberg HS, Lozano AM, Kennedy SH.

Front Hum Neurosci. 2017 Feb 24;11:74. doi: 10.3389/fnhum.2017.00074. eCollection 2017.

17.

Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials.

Luan S, Wan H, Wang S, Li H, Zhang B.

Neuropsychiatr Dis Treat. 2017 Feb 27;13:609-620. doi: 10.2147/NDT.S127453. eCollection 2017.

18.

A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.

Zanos P, Nelson ME, Highland JN, Krimmel SR, Georgiou P, Gould TD, Thompson SM.

eNeuro. 2017 Mar 7;4(1). pii: ENEURO.0285-16.2017. doi: 10.1523/ENEURO.0285-16.2017. eCollection 2017 Jan-Feb.

19.

The Global ECT-MRI Research Collaboration (GEMRIC): Establishing a multi-site investigation of the neural mechanisms underlying response to electroconvulsive therapy.

Oltedal L, Bartsch H, Sørhaug OJ, Kessler U, Abbott C, Dols A, Stek ML, Ersland L, Emsell L, van Eijndhoven P, Argyelan M, Tendolkar I, Nordanskog P, Hamilton P, Jorgensen MB, Sommer IE, Heringa SM, Draganski B, Redlich R, Dannlowski U, Kugel H, Bouckaert F, Sienaert P, Anand A, Espinoza R, Narr KL, Holland D, Dale AM, Oedegaard KJ.

Neuroimage Clin. 2017 Feb 14;14:422-432. doi: 10.1016/j.nicl.2017.02.009. eCollection 2017.

20.

Rapid and stable changes in maturation-related phenotypes of the adult hippocampal neurons by electroconvulsive treatment.

Imoto Y, Segi-Nishida E, Suzuki H, Kobayashi K.

Mol Brain. 2017 Mar 2;10(1):8. doi: 10.1186/s13041-017-0288-9.

Supplemental Content

Support Center